Roche and Illumina sign 15-year NGS testing deal in oncology
Roche Diagnostics Corp. and Illumina Inc. signed a 15-year, nonexclusive deal aimed at expanding the use of next-generation sequencing (NGS) testing in oncology. The overall goal is to broader access to NGS diagnostics on Illumina’s platforms for labs, clinicians, and patients.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com